{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:12:36Z","timestamp":1791414756638,"version":"4.3.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2005,11,17]],"date-time":"2005-11-17T00:00:00Z","timestamp":1132185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s00228-005-0051-5","type":"journal-article","created":{"date-parts":[[2005,11,17]],"date-time":"2005-11-17T18:28:45Z","timestamp":1132252125000},"page":"821-829","source":"Crossref","is-referenced-by-count":44,"title":["Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects"],"prefix":"10.1007","volume":"61","author":[{"given":"Christian","family":"Funck-Brentano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Bo\u00eblle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Verstuyft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Bornert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Becquemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,11,17]]},"reference":[{"key":"51_CR1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00008571-200004000-00001","volume":"10","author":"DS Streetman","year":"2000","unstructured":"Streetman DS, Bertino JS Jr,Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187\u2013216","journal-title":"Pharmacogenetics"},{"key":"51_CR2","doi-asserted-by":"crossref","first-page":"40S","DOI":"10.1177\/009127009703700121","volume":"37","author":"KT Kivisto","year":"1997","unstructured":"Kivisto KT, Kroemer HK (1997) Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 37:40S\u201348S","journal-title":"J Clin Pharmacol"},{"key":"51_CR3","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/clpt.1985.235","volume":"38","author":"\u200c\u200c\u200c\u200c\u200c\u200c\u200cB Schmid","year":"1985","unstructured":"Schmid B, Bircher J, Preisig R, Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618\u2013624","journal-title":"Clin Pharmacol Ther"},{"key":"51_CR4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3109\/00498258609050249","volume":"16","author":"A Kupfer","year":"1986","unstructured":"Kupfer A, Schmid B, Pfaff G (1986) Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 16:421\u2013433","journal-title":"Xenobiotica"},{"key":"51_CR5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0009-9236(99)70077-9","volume":"65","author":"T Tateishi","year":"1999","unstructured":"Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 65:570\u2013575","journal-title":"Clin Pharmacol Ther"},{"key":"51_CR6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1053\/cp.1999.v66.103401001","volume":"66","author":"L Tennez\u00e9","year":"1999","unstructured":"Tennez\u00e9 L, Verstuyft C, Becquemont L, Poirier JM, Wilkinson GR, Funck-Brentano C (1999) Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. Clin Pharmacol Ther 66:582\u2013588","journal-title":"Clin Pharmacol Ther"},{"key":"51_CR7","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0024-3205(02)01799-X","volume":"71","author":"MP Di Marco","year":"2002","unstructured":"Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP (2002) The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci 71:1149\u20131160","journal-title":"Life Sci"},{"key":"51_CR8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00008571-200007000-00006","volume":"10","author":"L Labbe","year":"2000","unstructured":"Labbe L, Sirois C, Pilote S, Arseneault M, Robitaille NM, Turgeon J et al. (2000) Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10:425\u2013438","journal-title":"Pharmacogenetics"},{"key":"51_CR9","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1472-8206.1999.tb00011.x","volume":"13","author":"J Chladek","year":"1999","unstructured":"Chladek J, Zimova G, Martinkova J, Tuma I (1999) Intra-individual variability and influence of urine collection period on dextromethorphan metabolic ratios in healthy subjects. Fundam Clin Pharmacol 13:508\u2013515","journal-title":"Fundam Clin Pharmacol"},{"key":"51_CR10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00008571-199810000-00005","volume":"8","author":"AD Kashuba","year":"1998","unstructured":"Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Shirey CS, Gotschall R et al. (1998) Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics 8:403\u2013410","journal-title":"Pharmacogenetics"},{"key":"51_CR11","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1373\/49.4.542","volume":"49","author":"WH Chou","year":"2003","unstructured":"Chou WH, Yan FX, Robbins-Weilert DK, Ryder TB, Liu WW, Perbost C et al. (2003) Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 49:542\u2013551","journal-title":"Clin Chem"},{"key":"51_CR12","first-page":"284","volume":"60","author":"C Sachse","year":"1997","unstructured":"Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284\u2013295","journal-title":"Am J Hum Genet"},{"key":"51_CR13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s002280050656","volume":"55","author":"N He","year":"1999","unstructured":"He N, Daniel HI, Hajiloo L, Shockley D (1999) Dextromethorphan O-demethylation polymorphism in an African-American population. Eur J Clin Pharmacol 55:457\u2013459","journal-title":"Eur J Clin Pharmacol"},{"key":"51_CR14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s002280050552","volume":"54","author":"V Lamba","year":"1998","unstructured":"Lamba V, Lamba JK, Dilawari JB, Kohli KK (1998) Genetic polymorphism of CYP2D6 in North Indian subjects. Eur J Clin Pharmacol 54:787\u2013791","journal-title":"Eur J Clin Pharmacol"},{"key":"51_CR15","first-page":"780","volume":"263","author":"C Funck-Brentano","year":"1992","unstructured":"Funck-Brentano C, Thomas G, Jacqz-Aigrain E, Poirier JM, Simon T, Bereziat G et al. (1992) Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther 263:780\u2013786","journal-title":"J Pharmacol Exp Ther"},{"key":"51_CR16","first-page":"453","volume":"9","author":"AD Kashuba","year":"1999","unstructured":"Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Gaedigk A et al. (1999) Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity. Pharmacogenetics 9:453\u2013462","journal-title":"Pharmacogenetics"},{"key":"51_CR17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0009-9236(99)70052-4","volume":"66","author":"ME Krecic-Shepard","year":"1999","unstructured":"Krecic-Shepard ME, Barnas CR, Slimko J, Gorski JC, Wainer IW, Schwartz JB (1999) In vivo comparison of putative probes of CYP3A4\/5 activity: erythromycin, dextromethorphan, and verapamil. Clin Pharmacol Ther 66:40\u201350","journal-title":"Clin Pharmacol Ther"},{"key":"51_CR18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1592\/phco.19.9.753.31536","volume":"19","author":"DI Min","year":"1999","unstructured":"Min DI, Ku YM, Vichiendilokkul A, Fleckenstein LL (1999) A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers. Pharmacotherapy 19:753\u2013759","journal-title":"Pharmacotherapy"},{"key":"51_CR19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00008571-199308000-00004","volume":"3","author":"E Jacqz-Aigrain","year":"1993","unstructured":"Jacqz-Aigrain E, Funck-Brentano C, Cresteil T (1993) CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197\u2013204","journal-title":"Pharmacogenetics"},{"key":"51_CR20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0378-4347(95)00574-9","volume":"678","author":"J Ducharme","year":"1996","unstructured":"Ducharme J, Abdullah S, Wainer IW (1996) Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 678:113\u2013128","journal-title":"J Chromatogr B Biomed Appl"},{"key":"51_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0378-4347(95)00431-9","volume":"678","author":"DR Jones","year":"1996","unstructured":"Jones DR, Gorski JC, Hamman MA, Hall SD (1996) Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4\/5 and 2D6 activity. J Chromatogr B Biomed Appl 678:105\u2013111","journal-title":"J Chromatogr B Biomed Appl"},{"key":"51_CR22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0009-9236(96)90194-0","volume":"60","author":"DR Jones","year":"1996","unstructured":"Jones DR, Gorski JC, Haehner BD, O\u2019Mara EM Jr, Hall SD (1996) Determination of cytochrome P450 3A4\/5 activity in vivo with dextromethorphan N\u2013demethylation. Clin Pharmacol Ther 60:374\u2013384","journal-title":"Clin Pharmacol Ther"},{"key":"51_CR23","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0006-8993(99)01125-7","volume":"821","author":"YC Chou","year":"1999","unstructured":"Chou YC, Liao JF, Chang WY, Lin MF, Chen CF (1999) Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan. Brain Res 821:516\u2013519","journal-title":"Brain Res"},{"key":"51_CR24","first-page":"990","volume":"260","author":"M Klein","year":"1992","unstructured":"Klein M, Musacchio JM (1992) High-affinity dextromethorphan and (+-3-(-3-hydroxyphenyl)-N-(1-propyl)piperidine binding sites in rat brain. Allosteric effects of ropizine. J Pharmacol Exp Ther 260:990\u2013999","journal-title":"J Pharmacol Exp Ther"},{"key":"51_CR25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1124\/jpet.103.060038","volume":"309","author":"RN Pechnick","year":"2004","unstructured":"Pechnick RN, Poland RE (2004) Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther 309:515\u2013522","journal-title":"J Pharmacol Exp Ther"},{"key":"51_CR26","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3171\/jns.1996.84.5.0860","volume":"84","author":"GK Steinberg","year":"1996","unstructured":"Steinberg GK, Bell TE, Yenari MA (1996) Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients. J Neurosurg 84:860\u2013866","journal-title":"J Neurosurg"},{"key":"51_CR27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2165\/00002018-199207030-00004","volume":"7","author":"JL Bem","year":"1992","unstructured":"Bem JL, Peck R (1992) Dextromethorphan. An overview of safety issues. Drug Saf 7:190\u2013199","journal-title":"Drug Saf"},{"key":"51_CR28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0009-9236(03)00220-0","volume":"74","author":"C Skarke","year":"2003","unstructured":"Skarke C, Jarrar M, Erb K, Schmidt H, Geisslinger G, Lotsch J (2003) Respiratory and miotic effects of morphine in healthy volunteers when P\u2013glycoprotein is blocked by quinidine. Clin Pharmacol Ther 74:303\u2013311","journal-title":"Clin Pharmacol Ther"},{"key":"51_CR29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.clpt.2003.08.011","volume":"74","author":"ED Kharasch","year":"2003","unstructured":"Kharasch ED, Hoffer C, Whittington D, Sheffels P (2003) Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 74:543\u2013554","journal-title":"Clin Pharmacol Ther"},{"key":"51_CR30","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa021986","volume":"348","author":"A Siddiqui","year":"2003","unstructured":"Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB et al. (2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348:1442\u20131448","journal-title":"N Engl J Med"},{"key":"51_CR31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0163-7258(01)00154-1","volume":"91","author":"P Mayer","year":"2001","unstructured":"Mayer P, Hollt V (2001) Allelic and somatic variations in the endogenous opioid system of humans. Pharmacol Ther 91:167\u2013177","journal-title":"Pharmacol Ther"},{"key":"51_CR32","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1073\/pnas.95.16.9608","volume":"95","author":"C Bond","year":"1998","unstructured":"Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L et al. (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95:9608\u20139613","journal-title":"Proc Natl Acad Sci USA"},{"key":"51_CR33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0378-4347(85)80074-8","volume":"338","author":"T East","year":"1985","unstructured":"East T, Dye D (1985) Determination of dextromethorphan and metabolites in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr 338:99\u2013112","journal-title":"J Chromatogr"},{"key":"51_CR34","first-page":"305","volume":"61","author":"C Verstuyft","year":"2003","unstructured":"Verstuyft C, Morin S, Yang J, Loriot MA, Barbu V, Kerb R et al. (2003) Nouvelle m\u00e9thode rapide et robuste de g\u00e9notypage du CYP2C9 et MDR1. Ann Biol Clin (Paris) 61:305\u2013309","journal-title":"Ann Biol Clin (Paris)"},{"key":"51_CR35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1096\/fasebj.1.5.3315805","volume":"1","author":"HJ Motulsky","year":"1987","unstructured":"Motulsky HJ, Ransnas LA (1987) Fitting curves to data using nonlinear regression: a practical and nonmathematical review. Faseb J 1:365\u2013374","journal-title":"Faseb J"},{"key":"51_CR36","first-page":"5","volume":"14","author":"H Akaike","year":"1976","unstructured":"Akaike H (1976) An information criterion (AIC). Math Sci 14:5\u20137","journal-title":"Math Sci"},{"key":"51_CR37","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2125.1987.tb03230.x","volume":"24","author":"D Larrey","year":"1987","unstructured":"Larrey D, Amouyal G, Tinel M, Letteron P, Berson A, Labbe G et al. (1987) Polymorphism of dextromethorphan oxidation in a French population. Br J Clin Pharmacol 24:676\u2013679","journal-title":"Br J Clin Pharmacol"},{"key":"51_CR38","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/clpt.1985.193","volume":"38","author":"E Steiner","year":"1985","unstructured":"Steiner E, Iselius L, Alvan G, Lindsten J, Sjoqvist F (1985) A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 38:394\u2013401","journal-title":"Clin Pharmacol Ther"},{"key":"51_CR39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00008571-199408000-00005","volume":"4","author":"KW Bock","year":"1994","unstructured":"Bock KW, Schrenk D, Forster A, Griese EU, Morike K, Brockmeier D et al. (1994) The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4:209\u2013218","journal-title":"Pharmacogenetics"},{"key":"51_CR40","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0009-9236(99)70018-4","volume":"66","author":"DS Streetman","year":"1999","unstructured":"Streetman DS, Ellis RE, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R et al. (1999) Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping. Clin Pharmacol Ther 66:535\u2013541","journal-title":"Clin Pharmacol Ther"},{"key":"51_CR41","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1365-2125.1988.tb05321.x","volume":"26","author":"J Kallio","year":"1988","unstructured":"Kallio J, Lindberg R, Huupponen R, Iisalo E (1988) Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio. Br J Clin Pharmacol 26:791\u2013795","journal-title":"Br J Clin Pharmacol"},{"key":"51_CR42","first-page":"504","volume":"28","author":"W Siegmund","year":"1N990","unstructured":"Siegmund W, Hanke W, Zschiesche M, Franke G, Biebler KE, Wilke A (1990) N-acetylation and debrisoquine type oxidation polymorphism in Caucasians \u2013 with reference to age and sex. Int J Clin Pharmacol Ther Toxicol 28:504\u2013509","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"51_CR43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2125.2001.01328.x","volume":"51","author":"S H\u00e4gg","year":"2001","unstructured":"H\u00e4gg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169\u2013173","journal-title":"Br J Clin Pharmacol"},{"key":"51_CR44","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/00912700122010627","volume":"41","author":"JS McCune","year":"2001","unstructured":"McCune JS, Lindley C, Decker JL, Williamson KM, Meadowcroft AM, Graff D et al. (2001) Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol 41:723\u2013731","journal-title":"J Clin Pharmacol"},{"key":"51_CR45","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0090-9556(24)15138-0","volume":"28","author":"M Vincent-Viry","year":"2000","unstructured":"Vincent-Viry M, Fournier B, Galteau MM (2000) Short communication. The effects of drinking and smoking on the CYP2D6 metabolic capacity. Drug Metab Dispos 28:617\u2013619","journal-title":"Drug Metab Dispos"},{"key":"51_CR46","first-page":"231","volume":"60","author":"CB Eap","year":"2004","unstructured":"Eap CB, Buclin T, Hustert E, Bleiber G, Golay KP, Aubert AC et al. (2004) Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 60:231\u2013236","journal-title":"Eur J Clin Pharmacol"},{"key":"51_CR47","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1067\/mcp.2002.128148b","volume":"72","author":"B Charbit","year":"2002","unstructured":"Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Brentano C (2002) Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther 72:514\u2013523","journal-title":"Clin Pharmacol Ther"},{"key":"51_CR48","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1067\/mcp.2000.110215","volume":"68","author":"JS McCune","year":"2000","unstructured":"McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J et al. (2000) In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 68:356\u2013366","journal-title":"Clin Pharmacol Ther"},{"key":"51_CR49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1015835215945","volume":"6","author":"SJ Vetticaden","year":"1989","unstructured":"Vetticaden SJ, Cabana BE, Prasad VK, Purich ED, Jonkman JH, de Zeeuw R et al. (1989) Phenotypic differences in dextromethorphan metabolism. Pharm Res 6:13\u201319","journal-title":"Pharm Res"},{"key":"51_CR50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00008571-199302000-00007","volume":"3","author":"JO Miners","year":"1993","unstructured":"Miners JO, Birkett DJ (1993) The misuse of urinary metabolite excretion data in drug metabolism studies. Pharmacogenetics 3:58\u201359","journal-title":"Pharmacogenetics"},{"key":"51_CR51","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/BF03018952","volume":"47","author":"AA Weinbroum","year":"2000","unstructured":"Weinbroum AA, Rudick V, Paret G, Ben-Abraham R (2000) The role of dextromethorphan in pain control. Can J Anaesth 47:585\u2013596","journal-title":"Can J Anaesth"},{"key":"51_CR52","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1176\/appi.ajp.157.2.304","volume":"157","author":"LH Price","year":"2000","unstructured":"Price LH, Lebel J (2000) Dextromethorphan-induced psychosis. Am J Psychiatry 157:304","journal-title":"Am J Psychiatry"},{"key":"51_CR53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","volume":"75","author":"C Marzolini","year":"2004","unstructured":"Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13\u201333","journal-title":"Clin Pharmacol Ther"},{"key":"51_CR54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0378-4274(01)00304-6","volume":"120","author":"O Tellingen van","year":"2001","unstructured":"van Tellingen O (2001) The importance of drug-transporting P-glycoproteins in toxicology. Toxicol Lett 120:31\u201341","journal-title":"Toxicol Lett"},{"key":"51_CR55","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1067\/mcp.2000.109156","volume":"68","author":"AJ Sadeque","year":"2000","unstructured":"Sadeque AJ, Wandel C, He H, Shah S, Wood AJ (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231\u2013237","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-005-0051-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-005-0051-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-005-0051-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T18:17:20Z","timestamp":1736101040000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-005-0051-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,17]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["51"],"URL":"https:\/\/doi.org\/10.1007\/s00228-005-0051-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,17]]}}}